Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy

Key Takeaways

• Anthony Slavin joins Infinimmune as SVP of Portfolio Strategy.
• Slavin previously advanced upadacitinib, risankizumab, and spesolimab to approval.
• He brings leadership experience from Atlas Venture, Kymera, AbbVie, Boehringer.
• Role focuses on shaping pipeline and selecting new antibody targets.
• Infinimmune’s Anthrobody platform uses human B cells for antibody discovery.

Pulse Analysis

Infinimmune’s Anthrobody® platform represents a shift in antibody discovery, tapping directly into the human immune repertoire to isolate fully human antibodies. By screening millions of memory B cells and applying the GLIMPSE™ language model, the company can identify high‑affinity candidates faster than traditional methods. This technology positions Infinimmune at the forefront of a market projected to exceed $200 billion by 2030, where speed and specificity are critical competitive differentiators.

Anthony Slavin’s appointment brings a rare blend of scientific depth and commercial acumen. Having guided multiple immunology assets—from early target validation at Boehringer Ingelheim to FDA‑approved therapies like upadacitinib—he understands the nuances of de‑risking programs and navigating regulatory pathways. His recent stint as an Entrepreneur in Residence at Atlas Venture also equips him with venture‑backed strategic insight, valuable for aligning Infinimmune’s pipeline with investor expectations and partnership opportunities.

The strategic timing of this hire signals Infinimmune’s intent to accelerate its go‑to‑market timeline. With Slavin overseeing portfolio prioritization, the firm can more effectively allocate resources toward high‑potential targets, potentially shortening the path from discovery to clinical trials. This could attract larger pharma collaborations and boost fundraising prospects, reinforcing Infinimmune’s position in a crowded biotech landscape where platform differentiation and execution speed are paramount.